شركة جميل للرعاية الصحية السعودية تتحالف مع شركة إيفلو الأمريكية لتطوير علاجات لفيروس كوفيد-19
![img](https://media.aljhealth.com/wp-content/uploads/2021/02/10131409/calender.png)
![Gulf News Logo](https://media.jameelhealth.com/wp-content/uploads/2021/04/04094413/Gulfnews-logo.jpg)
Gulfnews logo
Gulf News reported that Jameel Health has struck a partnership with US’ Evelo Biosciences to ‘develop and commercialize’ the latter’s inflammation product in the Middle East, Turkey and Africa.
The product candidate – ‘EDP1815’ – could also have its use as a therapeutic medicine for COVID-19. EDP1815 is an “investigational oral medicine” and Evelo is conducting a Phase 2 clinical trial for the treatment of psoriasis, as well as two trials in patients hospitalized with COVID-19. Evelo recently reported positive Phase 1b data in treating atopic dermatitis.
Read the full article in its original location here.
مقالات ذات صلة
للاتصالات الإعلامية، والاستفسارات الصحفية، يرجى التواصل معنا على media@alj.ae، أو الاتصال بنا على رقم 0906 448 4 971+ (توقيت الإمارات العربية المتحدة يسبق توقيت غرينتش بمقدار 4 ساعات)